Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
celecoxib + hyoscine-n-butyl bromide
- Development stage
- Preclinical
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of celecoxib, a selective COX-2 inhibitor NSAID, and hyoscine-n-butyl bromide, an anticholinergic antispasmodic drug. This combination leverages complementary mechanisms to provide enhanced pain relief. Celecoxib reduces inflammation and pain by inhibiting prostaglandin synthesis, while hyoscine-n-butyl bromide blocks muscarinic receptors in smooth muscle to relieve spasms. The combination has been studied for pain management during procedures like IUD insertion.
02
Targets
mAChR (Muscarinic acetylcholine receptors)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on celecoxib + hyoscine-n-butyl bromide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on celecoxib + hyoscine-n-butyl bromide.